JOURNAL OF ANTIBIOTICS抗生素杂志
JOURNAL OF ANTIBIOTICS(英文缩写 J ANTIBIOT),ISSN 0021-8820,eISSN 1881-1469,中文译名:抗生素杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.424 | Q2 |
| 2022 | 3.300 | Q2 |
| 2023 | 2.100 | Q3 |
| 2024 | 2.700 | Q2 |
| 2025 | 2.700 | Q3 |
JOURNAL OF ANTIBIOTICS 最新收录文献
-
1. New anti-fungal compounds 1PB1 and 45R from Streptomyces chrestomyceticus ADP4 target exo-β-1,3-glucanase and ergosterol biosynthesis in Candida albicans.
PMID:日期:2026-09-14The present study was aimed at understanding the mode of action of two newly reported anti-Candida compounds from Streptomyces chrestomyceticus strain ADP4: Phenyl 2'α,2'β,6'β-trimethyl cyclohexyl ketone (Chrestosyl cyclohexyl ketone; 1PB1) and trans-1-oxo-2,4-diacetylaminodecalin (Chrestosyl amino decalin; 45R). The docking studies revealed significant binding scores of CYP51 with 1PB1 (-7.4 kcal/mol) and with 45R (-7.6 kcal/mol). GC-MS sterol profiling of treated cells showed accumulation of lanosterol, confirming CYP51 inhibition. In vitro assays confirmed a consequent decrease in ergosterol biosynthesis, 69.92 ± 2.3% by 1PB1 and 55.48 ± 1.79% by 45R. In case of exo-β-1,3-glucanase, the binding scores were -8.4 kcal/mol with 1PB1 and -8.1 kcal/mol with 45R. Further, molecular dynamics simulations demonstrated that the complexes exhibited conformational stability, confirming strong and stable ligand binding compared to the apo forms. Inhibition of exo-β-1,3-glucanase as was confirmed through in vitro enzyme assays, wherein maximum inhibition of 94.6 ± 4.7% and 91.77 ± 1.7% were achieved at 52.7 µg/mL and 313.2 µg/mL of 1PB1 and 45R respectively. The results suggested that the compounds, 1PB1 and 45R, possessed a dual mode of action involving two cellular targets: CYP51 and exo-β-1,3-glucanase in Candida albicans.
-
2. Tsukubacyclinone, a novel angucyclinone compound with anti-inflammatory activity in synovial cell line SW982, produced by Streptomyces sp. K21-0141.
PMID:日期:2026-09-01Streptomyces species are prolific producers of structurally diverse secondary metabolites with a broad spectrum of biological activities. In this study, we isolated a novel angucyclinone compound, tsukubacyclinone (1), from the culture broth of Streptomyces sp. K21-0141. Tsukubacyclinone (1) exhibited potent anti-inflammatory effects in vitro. RNA sequencing of TNF-α-stimulated synovial cell line, SW982 revealed that tsukubacyclinone (1) downregulated pro-inflammatory genes, including IL1B and IL6, which was further validated by qPCR, without increasing LDH activity. KEGG pathway analysis indicated modulation of TNF, NF-κB, cytokine-cytokine receptor interaction, and JAK-STAT signaling. ELISA further confirmed a dose-dependent suppression of IL-1β and IL-6 protein. These findings suggest that tsukubacyclinone (1), as a novel angucyclinone-type compound, may target upstream cytokine signaling pathways to attenuate synovial inflammation, highlighting its potential as a disease-modifying agent for osteoarthritis and other chronic joint diseases. Future studies are warranted to investigate its in vivo pharmacological effects and molecular targets.
-
3. Macrolide antibiotic action, resistance, and tolerance, and approaches to improve their activity against Gram-negative bacteria.
PMID:日期:2026-09-01Macrolide antibiotics inhibit bacterial translation and are characterized by the presence of a macrocyclic lactone ring. First discovered as natural products of Streptomyces species, the potency of macrolide antibiotics against a diverse swath of bacterial pathogens has inspired continued efforts to develop semisynthetic derivatives with enhanced efficacy. Often used to treat community-acquired pneumonia, sexually-transmitted diseases, and gut infections, macrolides constitute one of the most commonly prescribed out-patient antibiotic classes in the world. However, those clinical successes have been tempered by the prevalence of macrolide resistance, observations of tolerance, and limited activity against many Gram-negative bacteria. Here, we review the macrolide antibiotic class by summarizing their discovery, biosynthesis, mechanism of action, and causes of failure, which include resistance and tolerance. We then discuss recent work that seeks to identify adjuvant compounds that could be delivered with macrolides to extend their spectrum of activity to more Gram-negative species, including those with multidrug-resistant strains.
-
4. Activation of hamiformamide production in the thermotolerant fungus Hamigera avellanea triggered by co-culture with animal immune cells.
PMID:日期:2026-09-01Understanding the mechanisms by which silent biosynthetic genes of secondary metabolites in microorganisms are activated is critical to developing ways to enhance natural product production. Our laboratory previously showed that co-culturing fungi with animal immune cells induces the production of secondary metabolites. In this study, we cultured cells at 37 °C (the optimal temperature for human cells) with thermotolerant fungi that can grow at this temperature. This optimized condition was expected to enhance production of otherwise silent metabolite genes. Eight thermotolerant fungi were co-cultured with J774.1 mouse macrophage-like cells at 28 or 37 °C. By comparing extracts, we identified metabolites specifically induced-or markedly enhanced-by co-culture at each temperature. Co-culture of Hamigera avellanea IFM 52957 with J774.1 cells at 37 °C enhanced the expression of two compounds, 1 and 2. Structural analyses identified 1 as 4-hydroxybenzaldehyde and 2 as (Z,Z)-N,N'-[1-[(4-hydroxyphenyl)methylene]-2-[(4-methoxyphenyl)methylene]-1,2-ethanediyl]bis-formamide, designated hamiformamide. Compound 2 inhibited nitric oxide production (IC = 49.1 µM), indicating its potential for modulating host immune signaling. In addition, the production of 2 increased under iron-depleted conditions, suggesting it is induced by iron competition with host immune cells.
-
5. Biosynthesis and enzymology of azaindane natural products.
PMID:日期:2026-09-01As a representative example of biosynthetic genome mining aimed at identifying biosynthetic gene clusters whose target is unknown core enzymes for known natural products, we review the biosynthesis of altemicidin (1), SB-203207 (2), and SB-203208 (3). Self-resistance gene-guided genome mining led to the identification of the responsible biosynthetic gene cluster, and heterologous expression of the cluster successfully confirmed the production of compounds 1-3. Biochemical analyses and single-gene expression studies demonstrated that the PLP-dependent enzyme SbzP is a core enzyme of this gene cluster. SbzP accepts β-NAD and SAM as substrates to generate the azaindane scaffold common to compounds 1-3. Subsequent in vitro assays revealed the downstream tailoring reactions, involving the α-ketoglutarate-dependent dioxygenase SbzQ, GNAT-type acyltransferase SbzI, ADP-ribose transferases SbzNHO, F420-dependent reductase SbzF, SAM-dependent methyltransferase SbzE, acyl-tRNA-dependent transferase SbzA, and GNAT-type acyltransferase SbzC, which collectively modify the SbzP product to yield the final structure of compound 3. Structural studies of SbzP and SbzI elucidated the molecular basis for substrate recognition and protein-protein interactions. This review highlights the novelty and utility of investigating biosynthetic gene clusters categorized as Group III and provides new insights into the biosynthesis of β-NAD-derived natural products.
-
6. "Lariocidin and ribosome-targeting lasso peptides as emerging antimicrobial agents against multidrug-resistant bacteria".
PMID:日期:2026-08-24Lasso peptides are ribosomally synthesized and post-translationally modified peptides (RiPPs) with mechanically constrained structures that provide high stability and target selectivity. Among them, lariocidin (LAR), produced by Paenibacillus sp. M2, represents a recently discovered peptide antibiotic with a ribosome-targeting mechanism distinct from classical antibacterial agents. lariocidin binds a distinct site within the bacterial 30S ribosomal subunit, involving interactions with 16S rRNA and aminoacyl-tRNA, thereby disrupting protein synthesis through translocation inhibition and miscoding. This binding mode may help reduce cross-resistance with established ribosome-targeting antibiotics, including aminoglycosides and tetracyclines. Preclinical evidence indicates broad antibacterial activity, including activity against multidrug-resistant pathogens such as Acinetobacter baumannii, together with low spontaneous resistance, limited mammalian cytotoxicity, minimal hemolysis, and in vivo efficacy in mouse infection models. However, lariocidin remains at an early developmental stage, and key questions related to pharmacokinetics/pharmacodynamics, formulation, scalable production, resistance surveillance, and independent validation remain unresolved. This review critically examines LAR within the broader context of ribosome-targeting lasso peptides and evaluates their potential as microbial peptide antibiotic scaffolds for future antimicrobial discovery. Clinical Trial Registration. Not applicable. This manuscript is a review article and does not report a clinical trial. Lariocidin (LAR) is a ribosomally synthesized and post-translationally modified lasso peptide produced by Paenibacillus sp. M2. Its constrained topology supports binding to a distinct site on the bacterial 30S ribosomal subunit, where LAR contacts 16S rRNA helices h31, h32, and h34 and the A-site tRNA, thereby inhibiting translocation and inducing miscoding. LAR retained activity against the resistance determinants evaluated experimentally and showed activity against selected multidrug-resistant pathogens, including Acinetobacter baumannii, with efficacy in one murine infection model and no detected cytotoxicity or substantial haemolysis in the reported assays. Further development requires pharmacokinetic/pharmacodynamic characterization, formulation and manufacturing studies, repeat-dose toxicology, and independent preclinical validation. Abbreviations: LAR, lariocidin; MDR, multidrug resistant; PK/PD, pharmacokinetics/pharmacodynamics; RiPP, ribosomally synthesized and post-translationally modified peptide.
-
7. Taxonomic characterization of Kribbella broussonetiae sp. nov., a novel rare actinomycete isolated from the rhizosphere soil of Broussonetia papyrifera.
PMID:日期:2026-08-21A novel rare actinomycete strain, WER1, was isolated from rhizosphere soil of Broussonetia papyrifera collected from Xiangtan City, Hunan province, China. Strain WER1 contained LL-diaminopimelic acid as the diagnostic diamino acid in the peptidoglycan. The major fatty acids (>5%) were anteiso-C, iso-C, anteiso-C and summed feature 9 (iso-C ω9c and/or 10-methyl C). The polar lipids were diphosphatidylglycerol, phosphatidylcholine, phosphatidylglycerol, and phosphatidylinositol. Sequence analysis of 16S rRNA gene indicated that the strain belonged to the genus Kribbella and shared highest similarities to Kribbella karoonensis Q41 (99.57%), Kribbella speibonae YM55 (99.35%), Kribbella soli FMN22 (99.28%), Kribbella podocarpi YPL1 (99.14%), and Kribbella swartbergensis HMC25 (99.13%). Phylogenetic analysis based on 16S rRNA gene, five house-keeping genes (gyrB, rpoB, relA, recA, and atpD) and whole genome sequences showed that strain WER1 is closely related to K. karoonensis JCM 14304 . But the average nucleotide identity and digital DNA-DNA hybridization values between strain WER1 and K. karoonensis JCM 14304 were much less than the 95-96% and 70% cut-off points recommended for delineating species. In addition, phenotypic and chemotaxonomic characteristics further confirmed that strain WER1 represents a new Kribbella species, for which the name Kribbella broussonetiae sp. nov. ( = MCCC 1K10349 = KCTC 59685 ), is proposed.
-
8. Two new diastereomeric sterigmatocystin derivatives from the culture broth of Hypomyces sp.
PMID:日期:2026-08-21Two new sterigmatocystin derivatives, named hyposterigmatocystin A and B (1 and 2), and three known compounds, 3a,12c-dihydro-8,12c-dihydroxy-6-methoxy-7H-furo[3',2':4,5]furo[2,3-c]xanthen-7-one (3), sterigmatocystin (4), and secosterigmatocystin (5) were isolated from the culture broth of Hypomyces sp. using various column chromatography techniques. The chemical structures of the isolated compounds were elucidated using spectroscopic methods and comparison with reported data. The isolated compounds were evaluated for their antibacterial activities against four Gram-positive bacteria, exhibiting MIC values ranging from 12.5 to exceeding 200 μg mL, with sterigmatocystin (4) being the most potent.
-
9. Biological profiling of structurally diverse LEGO-LPPOs reveals differences in antibacterial activity, cytocompatibility, and in vivo tolerability.
PMID:日期:2026-08-18Lipophosphonoxins represent a promising class of membrane-active antimicrobial agents with potential relevance for skin-targeted antimicrobial applications. Antibacterial activity of a panel of LEGO-lipophosphonoxin (LEGO-LPPO) compounds was evaluated by minimum inhibitory concentration (MIC) profiling against selected Gram-positive and Gram-negative bacterial strains. Cellular responses were subsequently assessed in human keratinocytes (HaCaT) and primary human dermal fibroblasts using MTS-based viability assays after 3 and 7 days of exposure across a broad concentration range. The tested LEGO-LPPOs exhibited pronounced variability in antibacterial activity and cytotoxicity profiles. Cell-based screening revealed marked heterogeneity in cellular responses, with fibroblasts consistently showing higher sensitivity than keratinocytes, particularly under prolonged exposure. Based on integrated MIC and IC₅₀ profiles, four representative compounds (DR_527P1, DR_556P1, DR_34P1, and DR_33P1) were selected for further functional characterization using keratinocyte migration assays, cytoskeletal organization analysis, and protein expression profiling. These compounds exerted distinct effects on cell migration, cytoskeletal organization and protein expression. In addition, in vivo tolerability was evaluated by maximal tolerated dose assessment in mice to provide a translational perspective on compound safety. Collectively, these findings show that selected structurally diverse LEGO-LPPO derivatives display divergent biological profiles that are not predicted by antibacterial potency alone. Rather than establishing a comprehensive structure-activity relationship (SAR), this study provides integrated biological profiling of representative LEGO-LPPO compounds and identifies structural diversity points and biological liabilities that should be considered during further optimization for local anti-infective applications.
-
10. Reimagining antimicrobial resistance: AI-driven predictive epidemiology and the C-AMRE framework for next-generation antibiotic discovery.
PMID:日期:2026-08-06Antimicrobial Resistance (AMR) has evolved from a clinically observed phenomenon into a complex, dynamic, and partially predictable evolutionary process. Traditional approaches centered on phenotypic detection and retrospective surveillance are increasingly inadequate to address the accelerating pace of resistance emergence. This review presents a paradigm shift toward predictive antimicrobial science, driven by the convergence of Evolutionary Intelligence (EI), Artificial Intelligence (AI), genomic surveillance, molecular simulation, and digital twin technologies. Leveraging whole-genome sequencing (WGS) and resistome analytics, AI models can identify latent resistance determinants and forecast evolutionary trajectories before clinical manifestation, enabling a transition from reactive to anticipatory intervention strategies. Central to this transformation is the concept of the Computational Antimicrobial Resistance Ecosystem (C-AMRE), an integrated, multi-layered framework that unifies data acquisition, predictive modeling, mechanistic simulation, and clinical feedback into a continuous learning system. Within this ecosystem, molecular simulations provide mechanistic insights into resistance at atomic and systems levels, while AI-driven pharmacology enables the design of novel antibiotics, antimicrobial peptides, and Nano-Adjuvants through generative and optimization-based approaches. The incorporation of digital twins further advances precision medicine by simulating patient-specific infection dynamics, pharmacokinetics/pharmacodynamics (PK-PD), and resistance evolution in real time, thereby enabling adaptive and personalized therapeutic strategies. Across micro-, meso-, and macro-scales, these technologies collectively redefine AMR as a systems-level phenomenon that can be modeled, predicted, and strategically managed. However, challenges related to data integration, model interpretability, validation, ethical governance, and global accessibility remain critical barriers to implementation. Despite these limitations, the integration of AI and computational frameworks positions antimicrobial research at the forefront of a new era, where antibiotics are no longer static interventions but adaptive components of intelligent, continuously evolving systems. This review highlights the transition from detection to prediction and ultimately to adaptive intervention, emphasizing the role of computational ecosystems in shaping the future of sustainable antimicrobial therapy.